Ardelyx, Inc.(ARDX)

Description: Ardelyx, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics to treat cardio-renal, gastrointestinal (GI), and metabolic diseases. Its lead product candidate is Tenapanor, a small molecule, orally administered inhibitor of NHE3, which is in three ongoing Phase II clinical trials for the treatment of patients with ESRD-HD and chronic kidney disease, as well as for constipation-predominant irritable bowel syndrome. The company also evaluates small molecule NaP2b inhibitors for the treatment of hyperphosphatemia in end stage renal disease. In addition, its other discovery and lead development programs consist of RDX009, RDX013, and RDX020 programs that are in research phase focusing on cardio-renal, GI, and metabolic diseases. Ardelyx, Inc. has a collaboration partnership agreement with AstraZeneca AB for the development and commercialization of tenapanor. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.

---

Keywords: Biotechnology Biopharmaceutical Phosphates Kidney Disease Metabolic Disease Chronic Kidney Disease Gastrointestinal Constipation Renal Disease Irritable Bowel Syndrome End Stage Renal Disease Stage Renal Disease Molecule Therapeutics Hyperphosphatemia Rockwell Medical Esrd

---

Home Page: www.ardelyx.com

ARDX Technical Analysis

400 Fifth Avenue
Waltham, MA 02451
United States
Phone: 510 745 1700

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)